Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study-Reference-Cited by-同舟云学术

Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study

Published:2019-02-21 Issue:5 Volume:38 Page:1413-1424
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Alten Rieke^ORCID,Mariette Xavier,Lorenz Hanns-Martin,Nüßlein Hubert,Galeazzi Mauro,Navarro Federico,Chartier Melanie,Heitzmann Julia,Poncet Coralie,Rauch Christiane,Le Bars Manuela

Funder

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

http://link.springer.com/article/10.1007/s10067-019-04449-w/fulltext.html

Reference45 articles.

1. Singh JA, Saag KG, Bridges SLJ, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68:1–25

2. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JM, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poor G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977. https://doi.org/10.1136/annrheumdis-2016-210715

3. Kiely PD (2016) Biologic efficacy optimization—a step towards personalized medicine. Rheumatology (Oxford) 55:780–788

4. Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le BM, Dougados M (2008) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67:547–554

5. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Teng J, Becker JC, Westhovens R (2008) Results of a two-year follow up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 58:953–963

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abatacept retention and clinical effectiveness in patients with rheumatoid arthritis in a real‐world setting in Taiwan;International Journal of Rheumatic Diseases;2024-07

2. Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort;Reumatismo;2024-06-24

3. Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioReg;Arthritis Research & Therapy;2024-02-08

4. Current pharmacological therapy for rheumatoid arthritis, factors for its effectiveness and associated complications: systematic review;Interdisciplinary Rehabilitation / Rehabilitacion Interdisciplinaria;2024-01-11

5. A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis;Rheumatology and Therapy;2023-10-19